Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Biotech
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
The liver disease drug candidate showed improvement over placebo in the phase 2b trial, while also outperforming Novo’s semaglutide once again.
Michael Gibney
Nov 9, 2026 3:33pm
Novo saying goodbye to longtime finance chief—Chutes & Ladders
Nov 6, 2026 10:12am
Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug
Sep 29, 2026 3:50am
Fierce Pharma
Novo struggles to appease restless investors with new strategy
Sep 21, 2026 10:50am
Novo corrals 3 new early-stage obesity drugs from Kallyope
Sep 18, 2026 11:23am
Fierce Pharma
Novo CEO talks embracing change and staying bullish amid rebrand
Sep 17, 2026 8:45am